09/508251

Fig.1

Fig.2


Counts
150
120
90
60
30
0
10^0
10^1
10^2
10^3
10^4
FL1-H

Fig.3


Counts
150
120
90
60
30
0
10^0
10^1
10^2
10^3
10^4
FL1 FITC

Fig.4



Fig.5


Growth Inhibition of Jurkat
5μl
10μl
% of Control
100
80
60
40
20
0
NT
8G2
11C8
2F12
13F1
7D2-E3
HYBRIDOMA

09/508251

Fig.6



Fig.7



Fig.8



Fig.9



Fig.10


Counts
0
20
40
60
80
100
M1
0
200
400
600
800
1000
FL3 PI

Fig.11


Counts
0
20
40
60
80
100
M1
0
200
400
600
800
1000
FL3-H

Fig.12A



Fig.12B



Best Available Copy

Fig.13A



Fig.13B



Fig.14



09/508251

Fig.15



Fig.16



Fig.17


980713.002
Propidium Iodide
Annexin V-FITC
1.06%
3.85%

Fig.18


980713.004
Propidium Iodide
Annexin V-FITC
38.81%
44.04%

Fig.19


980713.006
Propidium Iodide
Annexin V-FITC
4.17%
19.63%

Fig.20


980522.001
Propidium Iodide
Annexin V-FITC
1.05%
2.95%

Fig.21


980522.002
Propidium Iodide
Annexin V-FITC
2.11%
44.65%
10^0
10^1
10^2
10^3
10^4

Fig.22


980522.003
Propidium Iodide
Annexin V-FITC
1.23%
9.28%
10^0
10^1
10^2
10^3
10^4

Fig.23


980713.002
Propidium Iodide
Annexin V-FITC
1.06%
3.85%

Fig.24


980713.012
Propidium Iodide
Annexin V-FITC
23.79%
39.66%

Fig.25



Fig.26


Survival of KPMM2 SCID (MABL-2)
mIgG 50 μg/head
MABL-2 50 μg/head
MABL-2 5 μg/head
100
50
0
Survival Ratio (%)
0
50
100
150
Days

09/508251

Fig.27



Fig.28


Survival of KPMM2 SCID (MABL-2,F(ab')2)
mIgG 100 μg/head
MABL-2 10 μg/head
MABL-2 30 μg/head
MABL-2 100 μg/head
120
100
80
60
40
20
0
Survival Ratio (%)
0
20
40
60
80
100
Days

09/508251

Fig.29



09/508251

Fig.30